Retzius-sparing robot-assisted radical prostatectomy using the Revo-i robotic surgical system

surgical technique and results of the first human trial

Ki Don Chang, Ali Abdel Raheem, Youngdeuk Choi, Byungha Chung, KoonHo Rha

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To evaluate the safety and proficiency of the Revo-i ® robotic platform (Meere Company Inc.) in the treatment of prostate cancer (PCa). Patients and Methods: A prospective study was carried out on 17 patients with clinically localized PCa treated between 17 August 2016 and 23 February 2017 at our urology department using the Revo-i. Patients underwent Retzius-sparing robot-assisted radical prostatectomy (RS-RARP). The primary objective was to describe the RS-RARP step-by-step surgical technique using the Revo-i. In addition, the safety of the Revo-i was assessed according to intra-operative and the postoperative complications within 30 days of surgery. Early oncological outcomes were also assessed according to surgical margin status and biochemical recurrence (BCR). Continence was defined as use of no or only one pad. Surgeons’ satisfaction with the Revo-i was assessed using the Likert scale. Results: All surgeries were completed successfully, with no conversion to open or laparoscopic surgery. The median patient age was 72 years. The median docking time, console time, urethrovesical anastomosis time and estimated blood loss were 8 min, 92 min, 26 min and 200 mL, respectively. One patient was transfused intra-operatively as a result of blood loss of 1 500 mL. Postoperatively, two patients received blood transfusion, and there were no other serious/major complications. The median hospital stay was 4 days. At 3 months, four patients had positive surgical margins, one patient had BCR, and 15 patients were continent. Most of surgeons were satisfied with the Revo-i performance. Conclusions: The first human study for the treatment of patients with localized PCa using the Revo-i robotic surgical system was carried out successfully. The peri-operative, early oncological and continence outcomes are encouraging. Further prospective studies are warranted to support our preliminary results.

Original languageEnglish
Pages (from-to)441-448
Number of pages8
JournalBJU International
Volume122
Issue number3
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Robotics
Prostatectomy
Prostatic Neoplasms
Prospective Studies
Conversion to Open Surgery
Safety
Recurrence
Urology
Ambulatory Surgical Procedures
Blood Transfusion
Laparoscopy
Length of Stay

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{b59980d412ea4305936fb1c4dd7f70a9,
title = "Retzius-sparing robot-assisted radical prostatectomy using the Revo-i robotic surgical system: surgical technique and results of the first human trial",
abstract = "Objective: To evaluate the safety and proficiency of the Revo-i {\circledR} robotic platform (Meere Company Inc.) in the treatment of prostate cancer (PCa). Patients and Methods: A prospective study was carried out on 17 patients with clinically localized PCa treated between 17 August 2016 and 23 February 2017 at our urology department using the Revo-i. Patients underwent Retzius-sparing robot-assisted radical prostatectomy (RS-RARP). The primary objective was to describe the RS-RARP step-by-step surgical technique using the Revo-i. In addition, the safety of the Revo-i was assessed according to intra-operative and the postoperative complications within 30 days of surgery. Early oncological outcomes were also assessed according to surgical margin status and biochemical recurrence (BCR). Continence was defined as use of no or only one pad. Surgeons’ satisfaction with the Revo-i was assessed using the Likert scale. Results: All surgeries were completed successfully, with no conversion to open or laparoscopic surgery. The median patient age was 72 years. The median docking time, console time, urethrovesical anastomosis time and estimated blood loss were 8 min, 92 min, 26 min and 200 mL, respectively. One patient was transfused intra-operatively as a result of blood loss of 1 500 mL. Postoperatively, two patients received blood transfusion, and there were no other serious/major complications. The median hospital stay was 4 days. At 3 months, four patients had positive surgical margins, one patient had BCR, and 15 patients were continent. Most of surgeons were satisfied with the Revo-i performance. Conclusions: The first human study for the treatment of patients with localized PCa using the Revo-i robotic surgical system was carried out successfully. The peri-operative, early oncological and continence outcomes are encouraging. Further prospective studies are warranted to support our preliminary results.",
author = "Chang, {Ki Don} and {Abdel Raheem}, Ali and Youngdeuk Choi and Byungha Chung and KoonHo Rha",
year = "2018",
month = "9",
day = "1",
doi = "10.1111/bju.14245",
language = "English",
volume = "122",
pages = "441--448",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Retzius-sparing robot-assisted radical prostatectomy using the Revo-i robotic surgical system

T2 - surgical technique and results of the first human trial

AU - Chang, Ki Don

AU - Abdel Raheem, Ali

AU - Choi, Youngdeuk

AU - Chung, Byungha

AU - Rha, KoonHo

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Objective: To evaluate the safety and proficiency of the Revo-i ® robotic platform (Meere Company Inc.) in the treatment of prostate cancer (PCa). Patients and Methods: A prospective study was carried out on 17 patients with clinically localized PCa treated between 17 August 2016 and 23 February 2017 at our urology department using the Revo-i. Patients underwent Retzius-sparing robot-assisted radical prostatectomy (RS-RARP). The primary objective was to describe the RS-RARP step-by-step surgical technique using the Revo-i. In addition, the safety of the Revo-i was assessed according to intra-operative and the postoperative complications within 30 days of surgery. Early oncological outcomes were also assessed according to surgical margin status and biochemical recurrence (BCR). Continence was defined as use of no or only one pad. Surgeons’ satisfaction with the Revo-i was assessed using the Likert scale. Results: All surgeries were completed successfully, with no conversion to open or laparoscopic surgery. The median patient age was 72 years. The median docking time, console time, urethrovesical anastomosis time and estimated blood loss were 8 min, 92 min, 26 min and 200 mL, respectively. One patient was transfused intra-operatively as a result of blood loss of 1 500 mL. Postoperatively, two patients received blood transfusion, and there were no other serious/major complications. The median hospital stay was 4 days. At 3 months, four patients had positive surgical margins, one patient had BCR, and 15 patients were continent. Most of surgeons were satisfied with the Revo-i performance. Conclusions: The first human study for the treatment of patients with localized PCa using the Revo-i robotic surgical system was carried out successfully. The peri-operative, early oncological and continence outcomes are encouraging. Further prospective studies are warranted to support our preliminary results.

AB - Objective: To evaluate the safety and proficiency of the Revo-i ® robotic platform (Meere Company Inc.) in the treatment of prostate cancer (PCa). Patients and Methods: A prospective study was carried out on 17 patients with clinically localized PCa treated between 17 August 2016 and 23 February 2017 at our urology department using the Revo-i. Patients underwent Retzius-sparing robot-assisted radical prostatectomy (RS-RARP). The primary objective was to describe the RS-RARP step-by-step surgical technique using the Revo-i. In addition, the safety of the Revo-i was assessed according to intra-operative and the postoperative complications within 30 days of surgery. Early oncological outcomes were also assessed according to surgical margin status and biochemical recurrence (BCR). Continence was defined as use of no or only one pad. Surgeons’ satisfaction with the Revo-i was assessed using the Likert scale. Results: All surgeries were completed successfully, with no conversion to open or laparoscopic surgery. The median patient age was 72 years. The median docking time, console time, urethrovesical anastomosis time and estimated blood loss were 8 min, 92 min, 26 min and 200 mL, respectively. One patient was transfused intra-operatively as a result of blood loss of 1 500 mL. Postoperatively, two patients received blood transfusion, and there were no other serious/major complications. The median hospital stay was 4 days. At 3 months, four patients had positive surgical margins, one patient had BCR, and 15 patients were continent. Most of surgeons were satisfied with the Revo-i performance. Conclusions: The first human study for the treatment of patients with localized PCa using the Revo-i robotic surgical system was carried out successfully. The peri-operative, early oncological and continence outcomes are encouraging. Further prospective studies are warranted to support our preliminary results.

UR - http://www.scopus.com/inward/record.url?scp=85047662303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047662303&partnerID=8YFLogxK

U2 - 10.1111/bju.14245

DO - 10.1111/bju.14245

M3 - Article

VL - 122

SP - 441

EP - 448

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 3

ER -